Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–36.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942–50.

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718–27.

Article  CAS  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. 2020;31(12):1623–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.

Article  CAS  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.

Article  PubMed  PubMed Central  Google Scholar 

Tzetzo SL, Schultz E, Wang J, Rosenheck HR, Mahan S, Knudsen ES, et al. Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer. NPJ Breast Cancer. 2025;11(1)54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Migliaccio I, Bonechi M, Romagnoli D, Boccalini G, Galardi F, Guarducci C, et al. Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines. NPJ Breast Cancer. 2025;11(1)82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020;10(8):1174–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, et al. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome Med. 2023;15(1)55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2‑Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025;392(12):1189–202.

Article  CAS  PubMed  Google Scholar 

Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Ann Oncol. 2025.

Rugo H, Tolaney SM, Chan N, editors. Elacestrant in combination with everolimus or abemaciclib in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer: Phase 2 results from the ELEVATE study. San Antonio Breast Cancer Symposium; 2025 2025/12; San Antonio, TX.

Rugo H, Neven P, Martin M, editors. Giredestrant plus everolimus versus endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor therapy: Results from the evERA trial. San Antonio Breast Cancer Symposium; 2025 2025/12; San Antonio, TX.

Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025;393(6):569–80.

Article  CAS  PubMed  Google Scholar 

Bidard F‑C, Mayer EL, Park Y, editors. ctDNA-guided endocrine switching to camizestrant during first-line CDK4/6 inhibitor therapy in ER-positive, HER2-negative metastatic breast cancer: Updated results from the SERENA-6 trial. San Antonio Breast Cancer Symposium; 2025 2025/12; San Antonio, TX.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–40.

Article  PubMed  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-Based Therapy in 〈i〉PIK3CA〈/i〉-Mutated Advanced Breast Cancer. New England Journal of Medicine. 2024;391(17):1584–96.

Article  CAS  PubMed  Google Scholar 

Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, et al. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2025;393(2):151–61.

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, et al. LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA‑1. Annals of Oncology. 2025;36:S1677–S8.

Article  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523–33.

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025;43(9):1101–12.

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2‑Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023;41(24):4004–13.

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O’Shaughnessy JA, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391(22):2110–22.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423–33.

Article  CAS  PubMed  Google Scholar 

Jhaveri K, Park YH, Barrios C, editors. Sacituzumab govitecan versus chemotherapy as first cytotoxic therapy after endocrine treatment in HR-positive, HER2-negative metastatic breast cancer: Primary results from the phase III ASCENT-07 trial. San Antonio Breast Cancer Symposium; 2025 2025/12; San Antonio, TX.

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study. Ann Oncol. 2025.